更年期市場規模、佔有率、趨勢分析報告：按治療方法、地區、細分市場預測，2024-2030

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (North America, Europe, Latin America), And Segment Forecasts, 2024 - 2030

出版日期: 2023年11月24日 | 出版商:

Grand View Research | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

更年期市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球更年期市場規模將達244億美元，2024年至2030年複合年成長率為5.37%。

停經後症候群盛行率上升、人們對更年期相關健康問題的認知不斷提高以及女性健康應用程式的高採用率等因素預計將推動市場成長。

越來越多的研究支持營養補充食品荷爾蒙替代療法的益處，預計該市場將受到推動。市面上食品許多營養補充含有黑升麻、紅三葉草、大豆異黃酮和琥珀烯等成分。製造商也在努力開發新產品來解決更年期症狀。例如，Morphus 在 2023 年推出了多種補充品產品，以解決更年期和更年期的一些最緊迫的症狀。推出的第一個產品是 FiberUs，這是一種由瓜爾膠纖維製成的無味水溶性益生元纖維。

由於營養補充預約延遲、荷爾蒙替代治療重新推遲以及零售藥局和線上管道容易獲得成藥，疫情後對膳食補充劑和成藥的需求增加。然而，由於監管的放鬆和更年期意識的增強，市場目前正在穩定。

FDA核准用於治療潮熱和盜汗的藥物的快速增加也是推動市場成長的主要因素。 2023 年 5 月，FDA核准了一種新的非荷爾蒙藥物，用於解決更年期經常出現的盜汗和潮熱問題。這種處方藥稱為 fesolinetant，專為無法接受荷爾蒙治療並患有血管舒縮症狀的人（例如乳癌倖存者）而設計。該藥物以 Veozah 品牌出售。

更年期市場報告亮點

根據治療方法，營養補充食品領域預計將在 2023 年主導市場，並在預測期內實現最快的成長。該行業的成長可歸因於多種因素，包括老年人口的增加和創新產品的推出。例如，2021年4月，韓國營養補充食品Pulmuone推出了一款含有大豆和啤酒花萃取物的產品，用於治療與更年期相關的症狀。
成藥治療領域分為非荷爾蒙產品和荷爾蒙產品。已到更年期的女性擴大使用非處方 (OTC) 荷爾蒙產品。此細分市場的主要產品包括局部黃體酮、Ibuprofen、磊晶(DHEA) 和褪黑激素。
2023年，北美地區佔銷售佔有率最大。老年婦女的用餐意識不斷增強，對特定營養需求的需求也增加。
2022 年1 月，Amyris, Inc. 宣布已簽訂獨家協議，收購MenoLabs, LLC. 的資產，MenoLabs, LLC. 是一家由女性創辦的公司，專注於更年期治療、女性健康研究和提高公眾對更年期的了解。
2023年1月，女性健康品牌O Positive推出首款更年期維生素軟糖，為更年期女性提供一種方便又美味的方式來管理她們的症狀。

市場區隔和範圍
市場體系展望
- 母市場展望
- 相關/附隨市場展望
市場趨勢及展望
市場動態
- 更多女性進入閉經
- 提高對更年期及其治療的認知
- 擴大更年期照護的機會和創新
- 越來越多的研究支持營養補充食品的益處
市場抑制因素分析
- 與更年期和產品副作用相關的社會恥辱
- 缺乏明確規定
營商環境分析
- PESTLE分析
- 波特五力分析
COVID-19感染疾病的影響分析

第4章治療業務分析

更年期市場：治療變異分析
營養補充食品
成藥
- 荷爾蒙產品
- 非荷爾蒙產品

第5章區域業務分析

2023 年和 2030 年按地區分類的閉經市場佔有率
北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 瑞典
- 挪威
- 丹麥
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 泰國
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東/非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第6章競爭形勢

公司分類
策略規劃
- 併購
- 合作
- 新產品發布
參與企業概況
- Bayer AG
- Theramex
- Abbvie Inc.
- Abbott
- Pure Encapsulations, LLC
- Dr. Reddy's Laboratories Ltd.
- Rainbow Light
- PADAGIS LLC

簡介目錄圖表

Product Code: GVR-4-68039-434-2

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

Based on treatment, the dietary supplements treatment segment dominated the market in 2023 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
North America held the largest revenue share in 2023. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Treatment Segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. Gvr's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
- 3.4.1. Growing number of women undergoing menopause
- 3.4.2. Increasing awareness about menopause and its treatment
- 3.4.3. Growing opportunities and innovations in menopause treatment
- 3.4.4. Increasing research supporting advantages of dietary supplements
3.5. Market Restraint Analysis
- 3.5.1. Social stigma associated with menopause and adverse effects of products
- 3.5.2. Lack of well-defined regulations
3.6. Business Environment Analysis
- 3.6.1. PESTLE Analysis
- 3.6.2. Porter's Five Forces Analysis
3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis

4.1. Menopause Market: Treatment Movement Analysis
4.2. Dietary Supplements
- 4.2.1. Dietary Supplements Market, 2018 - 2030 (USD Million)
4.3. OTC Pharma Products
- 4.3.1. OTC Pharma Products Market, 2018 - 2030 (USD Million)
- 4.3.2. Hormonal Products
  - 4.3.2.1.1. Hormonal Products Market, 2018 - 2030 (USD Million)
- 4.3.3. Non-hormonal Products
  - 4.3.3.1.1. Non-hormonal Products Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

5.1. Menopause Market Share By Region, 2023 & 2030
5.2. North America
- 5.2.1. North America Menopause Market, 2018 - 2030 (USD Million)
- 5.2.2. U.S.
  - 5.2.2.1. Key Country Dynamics
  - 5.2.2.2. Regulatory Framework/Scenario
  - 5.2.2.3. Competitive Scenario
  - 5.2.2.4. U.S. Menopause Market, 2018 - 2030 (USD Million)
- 5.2.3. Canada
  - 5.2.3.1. Key Country Dynamics
  - 5.2.3.2. Regulatory Framework/Scenario
  - 5.2.3.3. Competitive Scenario
  - 5.2.3.4. Canada Menopause Market, 2018 - 2030 (USD Million)
5.3. Europe
- 5.3.1. Europe Menopause Market, 2018 - 2030 (USD Million)
- 5.3.2. UK
  - 5.3.2.1. Key Country Dynamics
  - 5.3.2.2. Regulatory Framework/Scenario
  - 5.3.2.3. Competitive Scenario
  - 5.3.2.4. Germany Menopause Market, 2018 - 2030 (USD Million)
- 5.3.3. Germany
  - 5.3.3.1. Key Country Dynamics
  - 5.3.3.2. Regulatory Framework/Scenario
  - 5.3.3.3. Competitive Scenario
  - 5.3.3.4. UK Menopause Market, 2018 - 2030 (USD Million)
- 5.3.4. France
  - 5.3.4.1. Key Country Dynamics
  - 5.3.4.2. Regulatory Framework/Scenario
  - 5.3.4.3. Competitive Scenario
  - 5.3.4.4. France Menopause Market, 2018 - 2030 (USD Million)
- 5.3.5. Italy
  - 5.3.5.1. Key Country Dynamics
  - 5.3.5.2. Regulatory Framework/Scenario
  - 5.3.5.3. Competitive Scenario
  - 5.3.5.4. Italy Menopause Market, 2018 - 2030 (USD Million)
- 5.3.6. Spain
  - 5.3.6.1. Key Country Dynamics
  - 5.3.6.2. Regulatory Framework/Scenario
  - 5.3.6.3. Competitive Scenario
  - 5.3.6.4. Spain Menopause Market, 2018 - 2030 (USD Million)
- 5.3.7. Sweden
  - 5.3.7.1. Key Country Dynamics
  - 5.3.7.2. Regulatory Framework/Scenario
  - 5.3.7.3. Competitive Scenario
  - 5.3.7.4. Sweden Menopause Market, 2018 - 2030 (USD Million)
- 5.3.8. Norway
  - 5.3.8.1. Key Country Dynamics
  - 5.3.8.2. Regulatory Framework/Scenario
  - 5.3.8.3. Competitive Scenario
  - 5.3.8.4. Norway Menopause Market, 2018 - 2030 (USD Million)
- 5.3.9. Denmark
  - 5.3.9.1. Key Country Dynamics
  - 5.3.9.2. Regulatory Framework/Scenario
  - 5.3.9.3. Competitive Scenario
  - 5.3.9.4. Denmark Menopause Market, 2018 - 2030 (USD Million)
5.4. Asia Pacific
- 5.4.1. Asia Pacific Menopause Market, 2018 - 2030 (USD Million)
- 5.4.2. Japan
  - 5.4.2.1. Key Country Dynamics
  - 5.4.2.2. Regulatory Framework/Scenario
  - 5.4.2.3. Competitive Scenario
  - 5.4.2.4. Japan Menopause Market, 2018 - 2030 (USD Million)
- 5.4.3. China
  - 5.4.3.1. Key Country Dynamics
  - 5.4.3.2. Regulatory Framework/Scenario
  - 5.4.3.3. Competitive Scenario
  - 5.4.3.4. China Menopause Market, 2018 - 2030 (USD Million)
- 5.4.4. India
  - 5.4.4.1. Key Country Dynamics
  - 5.4.4.2. Regulatory Framework/Scenario
  - 5.4.4.3. Competitive Scenario
  - 5.4.4.4. India Menopause Market, 2018 - 2030 (USD Million)
- 5.4.5. Australia
  - 5.4.5.1. Key Country Dynamics
  - 5.4.5.2. Regulatory Framework/Scenario
  - 5.4.5.3. Competitive Scenario
  - 5.4.5.4. Australia Menopause Market, 2018 - 2030 (USD Million)
- 5.4.6. Thailand
  - 5.4.6.1. Key Country Dynamics
  - 5.4.6.2. Regulatory Framework/Scenario
  - 5.4.6.3. Competitive Scenario
  - 5.4.6.4. Thailand Menopause Market, 2018 - 2030 (USD Million)
- 5.4.7. South Korea
  - 5.4.7.1. Key Country Dynamics
  - 5.4.7.2. Regulatory Framework/Scenario
  - 5.4.7.3. Competitive Scenario
  - 5.4.7.4. South Korea Menopause Market, 2018 - 2030 (USD Million)
5.5. Latin America
- 5.5.1. Latin America Menopause Market, 2018 - 2030 (USD Million)
- 5.5.2. Brazil
  - 5.5.2.1. Key Country Dynamics
  - 5.5.2.2. Regulatory Framework/Scenario
  - 5.5.2.3. Competitive Scenario
  - 5.5.2.4. Brazil Menopause Market, 2018 - 2030 (USD Million)
- 5.5.3. Mexico
  - 5.5.3.1. Key Country Dynamics
  - 5.5.3.2. Regulatory Framework/Scenario
  - 5.5.3.3. Competitive Scenario
  - 5.5.3.4. Mexico Menopause Market, 2018 - 2030 (USD Million)
- 5.5.4. Argentina
  - 5.5.4.1. Key Country Dynamics
  - 5.5.4.2. Regulatory Framework/Scenario
  - 5.5.4.3. Competitive Scenario
  - 5.5.4.4. Argentina Menopause Market, 2018 - 2030 (USD Million)
5.6. MEA
- 5.6.1. MEA Menopause Market, 2018 - 2030 (USD Million)
- 5.6.2. South Africa
  - 5.6.2.1. Key Country Dynamics
  - 5.6.2.2. Regulatory Framework/Scenario
  - 5.6.2.3. Competitive Scenario
  - 5.6.2.4. South Africa Menopause Market, 2018 - 2030 (USD Million)
- 5.6.3. Saudi Arabia
  - 5.6.3.1. Key Country Dynamics
  - 5.6.3.2. Regulatory Framework/Scenario
  - 5.6.3.3. Competitive Scenario
  - 5.6.3.4. Saudi Arabia Menopause Market, 2018 - 2030 (USD Million)
- 5.6.4. UAE
  - 5.6.4.1. Key Country Dynamics
  - 5.6.4.2. Regulatory Framework/Scenario
  - 5.6.4.3. Competitive Scenario
  - 5.6.4.4. UAE Menopause Market, 2018 - 2030 (USD Million)
- 5.6.5. Kuwait
  - 5.6.5.1. Key Country Dynamics
  - 5.6.5.2. Regulatory Framework/Scenario
  - 5.6.5.3. Competitive Scenario
  - 5.6.5.4. Kuwait Menopause Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

6.1. Company Categorization
6.2. Strategy Mapping
- 6.2.1. Merger& Acquisition
- 6.2.2. Collaborations
- 6.2.3. New Product Launch
6.3. Participant's overview
- 6.3.1. Bayer AG
  - 6.3.1.1. Overview
  - 6.3.1.2. Financial Performance
  - 6.3.1.3. Product Benchmarking
  - 6.3.1.4. Strategic Initiatives
- 6.3.2. Theramex
  - 6.3.2.1. Overview
  - 6.3.2.2. Financial Performance
  - 6.3.2.3. Product Benchmarking
  - 6.3.2.4. Strategic Initiatives
- 6.3.3. Abbvie Inc.
  - 6.3.3.1. Overview
  - 6.3.3.2. Financial Performance
  - 6.3.3.3. Product Benchmarking
  - 6.3.3.4. Strategic Initiatives
- 6.3.4. Abbott
  - 6.3.4.1. Overview
  - 6.3.4.2. Financial Performance
  - 6.3.4.3. Product Benchmarking
  - 6.3.4.4. Strategic Initiatives
- 6.3.5. Pure Encapsulations, LLC
  - 6.3.5.1. Overview
  - 6.3.5.2. Financial Performance
  - 6.3.5.3. Product Benchmarking
  - 6.3.5.4. Strategic Initiatives
- 6.3.6. Dr. Reddy's Laboratories Ltd.
  - 6.3.6.1. Overview
  - 6.3.6.2. Financial Performance
  - 6.3.6.3. Product Benchmarking
  - 6.3.6.4. Strategic Initiatives
- 6.3.7. Rainbow Light
  - 6.3.7.1. Overview
  - 6.3.7.2. Financial Performance
  - 6.3.7.3. Product Benchmarking
  - 6.3.7.4. Strategic Initiatives
- 6.3.8. PADAGIS LLC
  - 6.3.8.1. Overview
  - 6.3.8.2. Financial Performance
  - 6.3.8.3. Product Benchmarking
  - 6.3.8.4. Strategic Initiatives

簡介目錄圖表

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. Global dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
Table 4. Global OTC pharma products market estimates and forecast, 2018 - 2030 (USD Million)
Table 5. North America menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 6. North America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 7. U.S. menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 8. U.S. menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 9. Canada menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 10. Canada menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 11. Europe menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 12. Europe menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 13. UK menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 14. UK menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 15. Germany menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 16. Germany menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 17. France menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 18. France menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 19. Italy menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 20. Italy menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 21. Spain menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 22. Spain menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 23. Austria menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 24. Austria menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 25. Asia Pacific menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 26. Asia Pacific menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 27. China menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 28. China menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 29. Japan menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 30. Japan menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 31. India menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 32. India menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 33. South Korea menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 34. South Korea menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 35. Latin America menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 36. Latin America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 37. Brazil menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 38. Brazil menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 39. Mexico menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 40. Mexico menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 41. Middle East & Africa (MEA) menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 42. Middle East & Africa (MEA) menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 43. South Africa menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 44. South Africa menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)